Our Experts
Back to all ExpertsEric Kmiec, Ph.D
Executive Director and Chief Scientific Officer, The Gene Editing Institute
Expertise & Research Interests
- Gene Editing
- Biomedical Research
- Molecular Medicine
Education
- Ph.D., Molecular Biology / Biochemistry, University of Florida
- M.S., Cell Biology / Biochemistry, Southern Illinois University Edwardsville
- B.A., Microbiology, Rutgers University
Eric Kmiec, Ph.D
Executive Director and Chief Scientific Officer, The Gene Editing Institute
Eric B. Kmiec, Ph.D., is the founder and executive director of the Gene Editing Institute at ChristianaCare. He is also co-founder and chief scientific officer of CorriXR Therapeutics. Widely recognized for his pioneering work in the fields of molecular medicine and gene editing, Dr. Kmiec has developed CRISPR based genetic therapies for Sickle Cell Disease and Non-Small Cell Lung Cancer. Dr. Kmiec holds faculty appointments at the University of Delaware and The Wistar Institute and has been an NIH and National Science Foundation supported principal investigator for 35 years. His laboratory has made major discoveries in the CRISPR/gene editing field, and he serves on numerous editorial boards, authoring 169 peer-reviewed publications and books. He has served as primary mentor for 18 doctoral students and numerous postdoctoral scholars.
He is Editor-in-Chief of the journal, Gene and Genome Editing.
Dr. Kmiec is an accomplished speaker in human gene editing and its social and ethical impacts. He has received numerous service medals and awards, including the Eminent Scholar at Marshall University, Proudford Award in Sickle Cell Disease, Bio-Science Innovation Awards and the Philadelphia Life Science Innovator Award.
Multimedia
Experience
Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair
New App Can Reveal Unintentional Mutations of a CRISPR Edit
Affordable CRISPR App Reveals Unintended Mutations At Site Of CRISPR Gene Repair
Wilmington, DE, Feb. 11, 2020 -Scientists have developed an affordable, downloadable app that scans for potential unintended mistakes when CRISPR is used to repair mutations that cause disease. The app reveals potentially risky DNA alterations that could impede efforts to safely use CRISPR to correct mutations in conditions like sickle cell disease and cystic fibrosis.
Gene Editing Education Addresses Health Disparities
ChristianaCare Gene Editing Institute gets $1M grant to advance CRISPR work
Potential Inequities in New Medical Technologies
As headline-catching new technologies emerge—like tools to “edit” our DNA—researchers, doctors, patients and the general public are excited about the future of medicine and the research that informs its practice. For some, there are obvious and critical conversations taking place about the ethics of this research, including how we do it (think “CRISPR babies” in China) and the potential for edits (intentional or otherwise) that could be passed on to future generations.
These conversations are important, but they can overshadow another equally important question. Will all patients have equal access to these new technologies?
First U.S. use of CRISPR to directly target cancer will seek go-ahead from regulators
Trial to assess CRISPR genome editing platform in non-small cell lung cancer
Delaware-developed CRISPR cancer therapy edging closer to human testing
ChristianaCare continues to lessen cancer diagnostic time with new CRISPR techniques
“We have furthered the work and developed it into a method for improving cancer diagnosis,” said Kmiec...